Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone617-649-9200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.99 million
Profitability
Miscellaneous
Employees173
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable
Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions
What is Acceleron Pharma's stock symbol?
Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."
How were Acceleron Pharma's earnings last quarter?
Acceleron Pharma Inc (NASDAQ:XLRN) announced its earnings results on Monday, August, 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by $0.10. The biopharmaceutical company had revenue of $27.67 million for the quarter, compared to the consensus estimate of $28.72 million. Acceleron Pharma had a negative return on equity of 29.51% and a negative net margin of 318.84%. Acceleron Pharma's quarterly revenue was up 649.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.63) EPS. View Acceleron Pharma's Earnings History.
When is Acceleron Pharma's next earnings date?
What price target have analysts set for XLRN?
10 equities research analysts have issued 12 month price objectives for Acceleron Pharma's shares. Their predictions range from $45.00 to $78.00. On average, they anticipate Acceleron Pharma's stock price to reach $62.1250 in the next year. This suggests a possible upside of 33.4% from the stock's current price. View Analyst Price Targets for Acceleron Pharma.
What is the consensus analysts' recommendation for Acceleron Pharma?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acceleron Pharma.
What are Wall Street analysts saying about Acceleron Pharma stock?
Here are some recent quotes from research analysts about Acceleron Pharma stock:
- 1. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (7/20/2019)
- 2. HC Wainwright analysts commented, "Our $69 price target is based on probability-adjusted revenue forecasts for luspatercept, the company’s earlier stage pipeline and estimated year-end cash. We use the net present value of our revenue forecast through 2026, apply a 65% probability of success and a 2.5x price/sales multiple for luspatercept, and our year-end cash estimate of $7.85 to arrive at our price target. We use a 20% discount rate for the pipeline as it is above the marketed products discount rate due to development risks, but within the typical range of 15-25% for products in development." (6/4/2019)
Has Acceleron Pharma been receiving favorable news coverage?
News coverage about XLRN stock has trended somewhat positive this week, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Acceleron Pharma earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Acceleron Pharma.
Who are some of Acceleron Pharma's key competitors?
Some companies that are related to Acceleron Pharma include Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), bluebird bio (BLUE), Adaptive Biotechnologies (ADPT), Repligen (RGEN), argenx (ARGX), Moderna (MRNA), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA) and Halozyme Therapeutics (HALO).
What other stocks do shareholders of Acceleron Pharma own?
Who are Acceleron Pharma's key executives?
Acceleron Pharma's management team includes the folowing people:
- Mr. Habib J. Dable, CEO, Pres & Director (Age 50)
- Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 76)
- Mr. Kevin F. McLaughlin, Sr. VP, CFO & Treasurer (Age 63)
- Dr. Ravindra Kumar, Chief Scientific Officer & Sr. VP (Age 59)
- Dr. John D. Quisel, Exec. VP, Chief Bus. Officer & Sec. (Age 48)
Who are Acceleron Pharma's major shareholders?
Acceleron Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.34%), Vanguard Group Inc. (7.76%), Price T Rowe Associates Inc. MD (7.16%), Artal Group S.A. (2.85%), Janus Henderson Group PLC (2.49%) and Janus Henderson Group PLC (2.49%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Christopher Rovaldi, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar and Richard F Pops. View Institutional Ownership Trends for Acceleron Pharma.
Which major investors are selling Acceleron Pharma stock?
XLRN stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Artal Group S.A., Marshall Wace North America L.P., Westfield Capital Management Co. LP, Novo Holdings A S, Tiverton Asset Management LLC, Amundi Pioneer Asset Management Inc. and Bank of America Corp DE. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Habib J Dable, Jean George, John D Quisel, Kevin F Mclaughlin and Ravindra Kumar. View Insider Buying and Selling for Acceleron Pharma.
Which major investors are buying Acceleron Pharma stock?
XLRN stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Sofinnova Investments Inc., Nuveen Asset Management LLC, Candriam Luxembourg S.C.A., BlackRock Inc., Bamco Inc. NY, Vanguard Group Inc. and AXA. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.
How do I buy shares of Acceleron Pharma?
Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acceleron Pharma's stock price today?
One share of XLRN stock can currently be purchased for approximately $46.56.
How big of a company is Acceleron Pharma?
Acceleron Pharma has a market capitalization of $2.45 billion and generates $13.99 million in revenue each year. The biopharmaceutical company earns $-118,870,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe.View Additional Information About Acceleron Pharma.
What is Acceleron Pharma's official website?
How can I contact Acceleron Pharma?
Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]
MarketBeat Community Rating for Acceleron Pharma (NASDAQ XLRN)
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe XLRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XLRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
